

FIELD SAFETY NOTICE

Information on the Affected Product	Name – Reference and potentially affected batches: MAD-003993TP-2 — TCR beta Rearrangements Molecular Analysis kit. Batches: starting from BETA043 and subsequent batches MAD-003994BP-2 — IgH Rearrangements Molecular Analysis kit. Batches: starting from BP054 and subsequent batches MAD-003994TP-2 — TCR gamma Rearrangements Molecular Analysis kit. Batches: starting from TP054-3 and subsequent batches MAD-003999M — IgK-IgL Rearrangements Molecular Analysis kit. Batches: starting from KL034 and subsequent batches Description and Intended Use: Products intended for professional use in the context of in vitro diagnostic procedures. Non-automated kits for the qualitative detection of clonality in B- and T-cell lymphoproliferative processes by molecular analysis via PCR of immunoglobulin (Ig) and/or T-cell receptor (TCR) gene rearrangements, from genomic DNA previously extracted from peripheral blood lymphocytes, fresh frozen tissue or tissue fixed in buffered formalin and embedded in paraffin. The results serve as a diagnostic aid in patients with suspected lymphoproliferative diseases when histomorphological and immunohistochemical data are insufficient for the differential diagnosis between a reactive process and a malignant lymphoma. The specific intended use of each product is described in detail in its corresponding instructions for use (IFU).
ID Notice	#4430714538
Date	08/04/2026
Recipients	Customers and distributors who have received the affected products

Dear Customer/Distributor,

We are writing to inform you of a field safety notice regarding the products listed above.

DESCRIPTION OF THE PROBLEM IDENTIFIED

It has been identified that, in a small number of cases, the tubes included in kits containing the monotest PCR mix may exhibit abnormal performance whereby **the tube seal is not completely airtight**.

This behaviour does not necessarily occur at the time of sealing, but may arise after a period of storage and/or transport, which may result in:

- volume loss prior to use, or
- volume loss due to evaporation during thermal cycling (PCR)

Due to these characteristics, the problem may not be apparent prior to PCR and, in certain circumstances, may not be detected during routine use.

This behaviour has been observed with **very low frequency**, estimated at approximately **0.005% of the total number of PCR mix tubes supplied in the kits**.

Given the low probability of this incident occurring, this notification is being sent to the customer without the need to inform the Health Authority, as it is not considered a safety alert.

POTENTIAL RISKS ASSOCIATED WITH THE AFFECTED PRODUCT

Volume loss, whether prior to the start of the assay or during PCR may affect assay performance and primarily result in invalid or non-interpretable results, and in very rare cases in false-negative results, particularly in samples with low clonal load.

The impact of the problem may vary depending on the analytical method used:

- In capillary electrophoresis-based systems, the absence of amplification resulting from a possible loss of volume manifests as an absence of peaks on the electropherogram, which is usually interpreted as an invalid or non-interpretable result in accordance with the instructions for use.
- In gel electrophoresis-based systems (agarose or polyacrylamide), the absence of a signal could be interpreted as a negative result; in these cases, there is a low probability of false-negative results.

In accordance with the products' instructions for use, it is recommended that each sample be analysed in duplicate, which helps to detect non-reproducible results and further reduces the likelihood that an isolated incident will affect the final test result.

CORRECTIVE ACTIONS INITIATED BY VITRO S.A.

Vitro S.A. has initiated the following actions:

1. Ongoing investigation with the supplier to identify the root cause and implement a definitive solution that guarantees the correct functioning of the tube sealing system.
2. Search for and evaluation of alternative tubes from other suppliers, in accordance with the defined technical specifications, with the aim of ensuring the proper performance of the closure system.

ACTIONS TO BE TAKEN BY THE END USER

Before starting the PCR

1. In accordance with the instructions for use (IFU), it is recommended that each sample be analysed in duplicate, which helps to detect non-reproducible results and further reduces the likelihood that isolated incidents in individual tubes will affect the final interpretation of the result.
2. Briefly centrifuge the tubes to ensure that the entire volume is at the bottom of the tube.
3. Check that all tubes contain an equivalent volume as indicated in the instructions for use (IFU). Any tube with a volume visibly lower than expected should be considered abnormal and must not be used.
4. Check that all tubes are correctly sealed. Ensure that the cap is firmly secured and does not present looseness.

After the PCR

1. Check that the tubes are properly sealed. If any tube is found to be open or improperly sealed, discard the corresponding result and repeat the test.
2. Briefly centrifuge the tubes to collect any condensation and ensure that the entire volume is at the bottom of the tube.
3. Visually check the final volume in each tube:
 - a. The volume after PCR must be equivalent to the initial volume
 - b. Any visible reduction in volume should be considered abnormal
4. If a loss of volume is detected or suspected:
 - a. Discard the result
 - b. Repeat the assay

5. Pay particular attention to negative results, especially if:
- they are not confirmed in the duplicate
 - they do not correspond with the clinical suspicion
 - there are doubts regarding the condition of the tube

If any tube is found to have reduced volume, a defective seal or any other anomaly, please notify Vitro S.A. via the support form at <https://vitro.bio/soporte/> or by email: regulatory@vitro.bio

Review of previous results

A systematic review of previous results is not considered necessary if the user has followed the manufacturer's recommended instructions and has performed all amplifications for each sample in duplicate.

However, in the event of negative results that do not correspond to the clinical suspicion, or if any issue has been detected with the condition of the tubes, it is recommended that repeating the test be considered.

ACTIONS TO BE TAKEN BY THE DISTRIBUTOR

- Forward this communication to all customers who have received the affected products and ensure that they have received the information provided.
- In collaboration with Vitro S.A., implement all the actions described in this notice within your customer base.
- Ask customers to inform Vitro S.A. of any issues relating to the affected products.

Vitro S.A. regrets any inconvenience this situation may cause and thanks you for your cooperation.

For any further information, please do not hesitate to contact us at regulatory@vitro.bio.

Yours faithfully,



Alberto Roncero Franco
Regulatory Affairs Director
VITRO S.A

 vitro
T. +34 95 493 32 00 - F. +34 95 492 28 92
C/ Luis Fuentes Bejarano 60, local 3
41020 - Sevilla
www.vitro.bio
CIF - A 41361544

FIELD SAFETY NOTICE CONFIRMATION FORM

We kindly request that you complete and return this form within **10 days** of receipt, by emailing it to regulatory@vitro.bio.

☐ I have read, understood and implemented the necessary actions included in Field Safety Notice reference #4430714538 regarding the following products:

Reference - Product Name
MAD-003993TP-2 — TCR beta Rearrangements Molecular Analysis kit
MAD-003994TP-2 — TCR gamma Rearrangements Molecular Analysis kit
MAD-003994BP-2 — IgH Rearrangements Molecular Analysis kit
MAD-003999M — IgK-IgL Rearrangements Molecular Analysis kit

*DATE :

*NAME :

*POSITION :

*COMPANY/DEPARTMENT :

*ADDRESS :

*CITY :

*POST CODE:

*COUNTRY:

*TELEPHONE NUMBER :

*E-MAIL :

*SIGNATURE :

NOTE:

.....

Fields marked with an asterisk () are mandatory.*